THESEUS PHARMACEUTICALS INC's ticker is and the CUSIP is 88369M101. A total of 48 filers reported holding THESEUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,847 | +25.5% | 17,415 | +335.2% | 0.00% | – |
| Q2 2023 | $37,339 | -97.7% | 4,002 | -97.8% | 0.00% | – |
| Q1 2023 | $1,591,315 | +2085.6% | 179,202 | +1125.7% | 0.00% | – |
| Q4 2022 | $72,808 | +108.0% | 14,620 | +148.0% | 0.00% | – |
| Q3 2022 | $35,000 | 0.0% | 5,895 | -7.8% | 0.00% | – |
| Q2 2022 | $35,000 | -40.7% | 6,394 | +26.0% | 0.00% | – |
| Q1 2022 | $59,000 | -41.0% | 5,074 | -35.8% | 0.00% | – |
| Q4 2021 | $100,000 | – | 7,906 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 4,108,796 | $11,052,661 | 17.63% |
| Omega Fund Management, LLC | 711,479 | $1,913,879 | 1.76% |
| Lynx1 Capital Management LP | 702,415 | $1,889,496 | 1.25% |
| Orbimed Advisors | 17,713,600 | $47,649,584 | 1.01% |
| Nextech Invest Ltd. | 611,310 | $1,644,424 | 0.50% |
| Frazier Life Sciences Management, L.P. | 2,248,194 | $6,047,642 | 0.40% |
| Affinity Asset Advisors, LLC | 400,726 | $1,077,953 | 0.30% |
| DENALI ADVISORS LLC | 127,900 | $344,051 | 0.12% |
| Rock Springs Capital Management LP | 437,329 | $1,176,415 | 0.03% |
| Forefront Analytics, LLC | 17,672 | $47,539 | 0.03% |